Afatinib/axitinib/linifanib - BioGene Pharmaceutical

Drug Profile

Afatinib/axitinib/linifanib - BioGene Pharmaceutical

Alternative Names: Vaginal suppository ELTA - BioGene Pharmaceutical

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioGene Pharmaceutical
  • Class Imidazoles; Indazoles; Phenylurea compounds; Quinazolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Endometriosis

Most Recent Events

  • 16 Apr 2018 BioGene Pharmaceutical plans a phase I trial for Endometriosis in Switzerland, in May 2018 (NCT03481842)
  • 01 Jan 2018 Preclinical trials in Endometriosis in Switzerland (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top